Learn More
The most widely studied and used therapies for Alzheimer's disease (AD) are based on improving cholinergic function in the central nervous system. The acetylcholine-esterase inhibitors (ChEIs) tacrine, donepezil, rivastigmine, and galantamine are all approved, and the latter three are widely used for the symptomatic treatment of mild to moderate AD. Recent(More)
  • N Relkin
  • 2000
In current practice, the diagnosis of Alzheimer's disease is often delayed for several years after the initial onset of symptoms. Earlier diagnosis is desirable for several reasons. It allows the patient, family, and clinician to plan more effectively for the future, reduces the likelihood of catastrophic events such as motor vehicle accidents, and permits(More)
A number of naturally occurring biological intermediates have been found to inhibit competitively the activity of a highly purified NADP+-dependent oxidoreductase which catalyzes the simultaneous oxidation of gamma-hydroxybutyrate to succinic semialdehyde, and the reduction of D-glucuronate to L-gulonate. Of the inhibitors studied, those with the lowest Ki(More)
  • 1